Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03311126 · ClinicalTrials.gov registry record · Phase 2
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03311126 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 21 participants.
The verdict
NCT03311126, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their Mantle Cell Lymphoma (MCL) (i.e., prior single agent rituximab is permitted, prior involved-field radiotherapy is permitted).
Interventions
- DRUG Obinutuzumab
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-09-29 |
| Est. Completion | 2023-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03311126
The ClinicalTrials.gov registry entry for NCT03311126 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Obinutuzumab is the first listed.
NCT03311126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03311126 about?
NCT03311126 is a clinical study titled "Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma". This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received pri...
What is the current status of trial NCT03311126?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-09-29. Estimated completion is 2023-07-31.
What interventions are being tested in trial NCT03311126?
The interventions under investigation include: Obinutuzumab (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT03311126?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.